<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Child Adolesc Psychopharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">J Child Adolesc Psychopharmacol</journal-id>
<journal-id journal-id-type="publisher-id">cap</journal-id>
<journal-title-group>
<journal-title>Journal of Child and Adolescent Psychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1044-5463</issn>
<issn pub-type="epub">1557-8992</issn>
<publisher>
<publisher-name>Mary Ann Liebert, Inc.</publisher-name>
<publisher-loc>140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28817303</article-id>
<article-id pub-id-type="pmc">5725633</article-id>
<article-id pub-id-type="publisher-id">10.1089/cap.2017.0068</article-id>
<article-id pub-id-type="doi">10.1089/cap.2017.0068</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>CHRNA7</italic> Deletions are Enriched in Risperidone-Treated Children and Adolescents</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gillentine</surname>
<given-names>Madelyn A.</given-names>
</name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="aff1">
<sup>1,</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>White</surname>
<given-names>Janson J.</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grochowski</surname>
<given-names>Christopher M.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lupski</surname>
<given-names>James R.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1">
<sup>1,</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3,</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Schaaf</surname>
<given-names>Christian P.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1">
<sup>1,</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Calarge</surname>
<given-names>Chadi A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<aff id="aff1"><label><sup>1</sup></label>Department of Molecular and Human Genetics, <institution>Baylor College of Medicine</institution>, Houston, Texas.</aff>
<aff id="aff2"><label><sup>2</sup></label>Jan and Dan Neurological Research Institute, <institution>Texas Children's Hospital</institution>, Houston, Texas.</aff>
<aff id="aff3"><label><sup>3</sup></label>Human Genome Sequencing Center, <institution>Baylor College of Medicine</institution>, Houston, Texas.</aff>
<aff id="aff4"><label><sup>4</sup></label><institution>Texas Children's Hospital</institution>, Houston, Texas.</aff>
<aff id="aff5"><label><sup>5</sup></label>Menninger Department of Psychiatry and Behavioral Sciences, <institution>Baylor College of Medicine</institution>, Houston, Texas.</aff>
</contrib-group>
<author-notes>
<corresp id="fn1"><bold>Funding:</bold> This study was funded by a 2005 and a 2007 Young Investigator Award, a Fraternal Order of Eagle Diabetes Research Center pilot grant, and by the National Institutes of Health (RR024979, R21MH080968, and K23MH085005). Work in Dr. Schaaf's and Lupski's laboratories was supported in part by IDDRC grant number 1 U54 HD083092 from the Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development. Ms. Gillentine was supported by Award Number T32GM008307 from the National Institute of General Medical Sciences. Mr. White was supported by the Smith-Magenis Syndrome Research Foundation's Research Initiative. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.</corresp>
<corresp>
<addr-line>Address correspondence to:</addr-line>
<addr-line>
<italic>Chadi A. Calarge, MD</italic>
</addr-line>
<addr-line>
<italic>Menninger Department of Psychiatry and Behavioral Sciences</italic>
</addr-line>
<institution>
<italic>Baylor College of Medicine</italic>
</institution>
<addr-line>
<italic>1102 Bates Avenue, Suite 790</italic>
</addr-line>
<addr-line>
<italic>Houston, TX 77030</italic>
</addr-line>
<italic>E-mail:</italic>
<email xlink:href="mailto:chadi.calarge@bcm.edu">chadi.calarge@bcm.edu</email>
</corresp>
<corresp>
<addr-line>
<italic>Christian P. Schaaf, MD, PhD</italic>
</addr-line>
<addr-line>
<italic>Department of Molecular and Human Genetics</italic>
</addr-line>
<institution>
<italic>Baylor College of Medicine</italic>
</institution>
<addr-line>
<italic>1250 Moursund Street, Suite 1325</italic>
</addr-line>
<addr-line>
<italic>Houston, TX 77030</italic>
</addr-line>
<italic>E-mail:</italic>
<email xlink:href="mailto:schaaf@bcm.edu">schaaf@bcm.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>01</day>
<month>12</month>
<year>2017</year>
<!--string-date: December 2017-->
</pub-date>
<pub-date pub-type="epub">
<day>01</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>27</volume>
<issue>10</issue>
<fpage>908</fpage>
<lpage>915</lpage>
<permissions>
<copyright-statement>Copyright 2017, Mary Ann Liebert, Inc.</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="cap.2017.0068.pdf" xlink:type="simple"></self-uri>
<abstract>
<title>Abstract</title>
<p><bold><italic>Objective:</italic></bold> Aggression is among the most common indications for referral to child and adolescent mental health services and is often challenging to treat. Understanding the biological underpinnings of aggression could help optimize treatment efficacy. Neuronal nicotinic acetylcholine receptors (nAChRs), specifically the α7 nAChR, encoded by the gene <italic>CHRNA7</italic>, have been implicated in aggressive behaviors in animal models as well as humans. Copy number variants (CNVs) of <italic>CHRNA7</italic> are found in individuals with neuropsychiatric disorders, often with comorbid aggression. In this study, we aimed to determine the prevalence of <italic>CHRNA7</italic> CNVs among individuals treated with risperidone, predominantly for irritability and aggression.</p>
<p><bold><italic>Methods:</italic></bold> Risperidone-treated children and adolescents were assessed for <italic>CHRNA7</italic> copy number state using droplet digital PCR and genomic quantitative PCR. Demographic, anthropometric, and clinical data, including the <italic>Child Behavior Checklist</italic> (CBCL), were collected and compared across individuals with and without the <italic>CHRNA7</italic> deletion.</p>
<p><bold><italic>Results:</italic></bold> Of 218 individuals (90% males, mean age: 12.3 ± 2.3 years), 7 (3.2%) were found to carry a <italic>CHRNA7</italic> deletion and one proband carried a <italic>CHRNA7</italic> duplication (0.46%). T-scores for rule breaking, aggression, and externalizing behavior factors of the CBCL were higher in the deletion group, despite taking 58% higher dose of risperidone.</p>
<p><bold><italic>Conclusions:</italic></bold>
<italic>CHRNA7</italic> loss may contribute to a phenotype of severe aggression. Given the high prevalence of the deletion among risperidone-treated youth, future studies should examine the therapeutic potential of α7 nAChR-targeting drugs to target aggression associated with <italic>CHRNA7</italic> deletions.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title><bold>Keywords:</bold> </title>
<kwd>
<italic>CHRNA7</italic>
</kwd>
<kwd>15q13.3 microdeletion</kwd>
<kwd>aggression</kwd>
<kwd>disruptive behaviors</kwd>
<kwd>risperidone</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="3"></table-count>
<ref-count count="35"></ref-count>
<page-count count="8"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>